In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Keros Therapeutics Inc (NASDAQ: KROS) closed at $15.09 in the last session, down -5.03% from day before closing price of $15.89. In other words, the price has decreased by -$5.03 from its previous closing price. On the day, 0.52 million shares were traded. KROS stock price reached its highest trading level at $15.89 during the session, while it also had its lowest trading level at $15.06.
Ratios:
We take a closer look at KROS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.89 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.55. For the most recent quarter (mrq), Quick Ratio is recorded 21.11 and its Current Ratio is at 21.11. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Wedbush Downgraded its Outperform to Neutral on January 17, 2025, while the target price for the stock was maintained at $15.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 12 ’25 when Rovaldi Christopher bought 85,306 shares for $15.71 per share.
ADAR1 Capital Management, LLC bought 934,258 shares of KROS for $9,464,512 on Apr 09 ’25. The 10% Owner now owns 4,392,737 shares after completing the transaction at $10.13 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 645378880 and an Enterprise Value of -59374404. As of this moment, Keros’s Price-to-Earnings (P/E) ratio for their current fiscal year is 48.16. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 31.07. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.63 while its Price-to-Book (P/B) ratio in mrq is 0.87. Its current Enterprise Value per Revenue stands at -0.255 whereas that against EBITDA is -35.511.
Stock Price History:
The Beta on a monthly basis for KROS is 1.13, which has changed by -0.7573175 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $72.37, while it has fallen to a 52-week low of $9.12. The 50-Day Moving Average of the stock is -1.07%, while the 200-Day Moving Average is calculated to be 11.75%.
Shares Statistics:
According to the various share statistics, KROS traded on average about 432.52K shares per day over the past 3-months and 543240 shares per day over the past 10 days. A total of 40.62M shares are outstanding, with a floating share count of 33.91M. Insiders hold about 16.50% of the company’s shares, while institutions hold 87.64% stake in the company. Shares short for KROS as of 1759190400 were 3867988 with a Short Ratio of 8.94, compared to 1756425600 on 4501318. Therefore, it implies a Short% of Shares Outstanding of 3867988 and a Short% of Float of 14.92.
Earnings Estimates
The firm’s stock currently is rated by 8.0 analysts. The consensus estimate for the next quarter is -$0.96, with high estimates of -$0.29 and low estimates of -$1.63.
Analysts are recommending an EPS of between $2.46 and -$0.21 for the fiscal current year, implying an average EPS of $1.0. EPS for the following year is -$4.01, with 8.0 analysts recommending between -$0.75 and -$5.81.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for KROS’s current fiscal year. The highest revenue estimate was $250M, while the lowest revenue estimate was $220M, resulting in an average revenue estimate of $235.19M. In the same quarter a year ago, actual revenue was $3.55M
